Serum thymosin alpha 1 levels in normal and pathological conditions

Expert Opinion on Biological Therapy

Volumn 18, Issue , 2018, Pages 13-21

  Pica, Francesca ^a   Gaziano, Roberta ^a   Casalinuovo, Ida Antonia ^a   Moroni, Gabriella ^a   Buè, Cristina ^a   Limongi, Dolores ^b   D’Agostini, Cartesio ^a   Tomino, Carlo ^b   Perricone, Roberto ^a   Palamara, Anna Teresa ^b,c   Sinibaldi Vallebona, Paola ^a   Garaci, Enrico ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

cancer; chronic inflammatory autoimmune diseases; immune system; immune deficiency; infectious diseases; Serum thymosin a 1

Indexed keywords

THYMOSIN ALPHA1; VACCINE; IMMUNOLOGICAL ADJUVANT;

CIRCADIAN RHYTHM; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DEREGULATION; DRUG BIOAVAILABILITY; DRUG TOLERANCE; EFFECTIVE DOSE (PHARMACOLOGY); HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION; INFLAMMATION; MALIGNANT NEOPLASM; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACOKINETICS; PREDICTION; PSORIATIC ARTHRITIS; REVIEW; SEPSIS; THERAPY EFFECT; TREATMENT RESPONSE; BLOOD; COMMUNICABLE DISEASE; DISEASES; HEPATITIS B; HOMEOSTASIS; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; COMMUNICABLE DISEASES; DISEASE; HEPATITIS B; HOMEOSTASIS; HUMANS; NEOPLASMS; SEPSIS; THYMALFASIN; VACCINES;

EID: 85051057890     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2018.1474197     Document Type: Review

References (97)

1. Low TLK, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J Biol Chem. 1979;254:981–986
2. Low TLK, Goldstein AL., The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1. J Biol Chem. 1979;254:987–995
3. Sarandeses CS, Covelo G, D_ıaz-Jullien C, et al. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem. 2003;278:13286–13293
4. Franco FJ, Diaz C, Barcia M, et al. Thymosin alpha 1 is a native peptide in several tissues. Biochim Biophys Acta. 1992;1120:43–48
5. Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside. Ann NY Acad Sci. 2007;1112:225–234
6. Yao Q, Doan LX, Zhang R, et al. Thymosin alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. Immunol Lett. 2007;110:110–120
7. Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin alpha1 requires the TRAF6 signaling pathway. EMBO Rep. 2005;6:531–537
8. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103:4232–4239
9. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108:2265–2274
10. Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann NY Acad Sci. 2007;1112:326–338
11. Bonifazi P, D’angelo C, Fallarino F, et al. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci. 2010;1194:1–5
12. Umeda Y, Sakamoto A, Nakamura J, et al. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother. 1983;15:78–83
13. Di Francesco P, Pica F, Gaziano R, et al. In vivo recovery of natural killer cell activity by the association of thymosin alpha 1 and cytokines during cocaine administration. Med Sci Res. 1994;22:41–42
14. Favalli C, Jezzi T, Mastino A, et al. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother. 1985;20:189–192
15. Serrate SA, Schulof RS, Leondaridis L, et al. Modulation of human natural killer cell cytotoxic activity, limphokine production, and interleukine-2 receptor expression by thymic hormones. J Immunol. 1987;139:2338–2343
16. Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of Lewis lung carcinoma in mice. Int J Cancer. 1990;50:493–499
17. Garaci E, Mastino A, Pica F, et al. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother. 1990;32:154–160
18. Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer. 1994;57:701–705
19. Silecchia G, Guarino E, Sinibaldi-Vallebona P, et al. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother. 1999;48:172–178
20. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin alpha 1 and interferon alpha in human immunodeficiency virus infection. Int J Clin Lab Res. 1994;24:23–28
21. Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. 1998;18:3571–3578
22. Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin alpha 1 and its pleiotropy. Ann N Y Acad Sci. 2012;1269:1–6
23. Shrivastava P, Singh SM, Singh N. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage derived dendritic cells. J Biomed Sci. 2004;11:623–630
24. Peng Y, Chen Z, Yu W, et al. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol Int. 2008;32:1265–1271
25. Loggi E, Gramenzi A, Margotti M, et al. In vitro effect of thymosin alpha 1 and interferon alpha on Th1 and Th2 cytokine synthesis in patients with eAg negative chronic hepatitis B. J Viral Hepat. 2008;15:442–448
26. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA. 1986;83:6107–6111
27. Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. 1989;11:789–800
28. Leichtling KD, Serrate SA, Sztein MB. Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol. 1990;12:19–29
29. Hsia J, Sarin N, Oliver JH, et al. Aspirin and thymosin increase interleukin-2 and interferon gamma production by human peripheral blood lymphocytes. Immunopharmacology. 1989;17:167–173
30. Garaci E, Pica F, Serafino A, et al. Thymosin α1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012 Oct;1269:26–33
31. Garaci E, Pica F, Matteucci C, et al. Historical review on thymosin α1 in oncology: preclinical and clinical experiences. Expert Opin Biol Ther. 2015;15(Suppl 1):S31–S39
32. Giuliani C, Napolitano G, Mastino A, et al. Thymosin alpha 1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30:778–786
33. Palamara A, Bue M, Savini P, et al. Thymosin alpha 1 inhibits Sendai virus replication: involvement of intracellular redox state. 6th International Expert Forum of Immunotherapy and Gene Therapy, Florence, Italy; 1998
34. Moody TW, Fagarasan M, Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res. 1993;53:5214–5218
35. Nepravishta R, Mandaliti W, Eliseo T, et al. Thymosin a1 inserts N terminus into model membranes assuming a helical conformation. Expert Opin Biol Ther. 2015;15:S71–81
36. Mandaliti W, Nepravishta R, Sinibaldi Vallebona P, et al. Thymosin a1 interacts with exposed phosphatidylserine in membrane models and in cells and uses serum albumin as carrier. Biochemistry. 2016;55:1462–1472
37. Mandaliti W, Nepravishta R, Pica F, et al. Thymosin α1 interacts with hyaluronic acid electrostatically by its terminal sequence LKEKK. Molecules. 2017 Oct 27;22(11):E1843
38. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9:593–608
39. Tuthill C, Rios I, De Rosa A, et al. Thymosin α1 continues to show promise as an enhancer for vaccine response. Ann N Y Acad Sci. 2012 Oct;1270:21–27
40. Tuthill CW, King RS. Thymosin alpha 1–a peptide immune modulator with a broad range of clinical applications. Clin Exp Pharmacol. 2013;3:133
41. Camerini R, Garaci E. Historical review of thymosin α 1 in infectious diseases. Expert Opin Biol Ther. 2015;15(Suppl 1):S117–S127
42. Qiu SJ, Zhou ZG, Shen F, et al. A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - first announcement of the protocol. Expert Opin Biol Ther. 2015;15(Suppl 1):S133–S137
43. Wu X, Jia J, You H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 2015;15(Suppl 1):S129–S132
44. Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 2012 Jan;19(Suppl 1):52–59
45. Liu F, Wang HM, Wang T, et al. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis. 2016 Sep 15;16:488
46. Wang FY, Fang B, Qiang XH, et al. The efficacy and immunomodulatory effects of ulinastatin and thymosin α1 for sepsis: a systematic review and meta-analysis. Biomed Res Int. 2016;2016:9508493
47. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013 Jan 17;17(1):R8
48. Wang X, Li W, Niu C, et al. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation. 2011 Jun;34(3):198–202
49. Jia Z, Feng Z, Tian R, et al. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. Immunopharmacol Immunotoxicol. 2015;37(4):388–392
50. Wara DW, Goldstein AL, Doyle NE, et al. Thymosin activity in patients with cellular immunodeficiency. N Engl J Med. 1975 Jan 9; 292(2):70–74
51. Goldstein AL. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007 Sep;1112:1–13. Epub 2007 Jun 28
52. White A, Goldstein AL. The endocrine role of the thymus and its hormone, thymosin, in the regulation of the growth and maturation of host immunological competence. Adv Metab Disord. 1975;8:359–374
53. Chretien PB, Lipson SD, Makuch R, et al. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treat Rep. 1978;62(11):1787–1790
54. Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod. 1985;4:147–158
55. Lopez M, Carpano S, Cavaliere R, et al. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol. 1994;5(8):741–766
56. Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin alpha 1 and low-dose interferon alpha after dacarbazine in advanced melanoma. Melanoma Res. 2000;10:189–192
57. Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010;28(10):1780–1787
58. Garaci E, Lopez M, Bonsignore G, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. 1995;31A(13–14):2403–2405
59. Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase II controlled trial. Anticancer Res. 1996;16:1001–1004
60. Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. 2011;(2):CD003993
61. Sherman KE, Jones CC, Goldstein AL, et al. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol. 1991;4(3):195–199. Fall
62. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991 Sep;14(3):409–415
63. Rasi G, Mutchnick MG, Di Virgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B. J Viral Hepat. 1996 Jul;3(4):191–196
64. Rasi G, DiVirgilio D, Mutchnick MG, et al. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut. 1996 Nov;39(5):679–683
65. Rasi G, Pierimarchi P, Sinibaldi Vallebona P, et al. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int Immunopharmacol. 2003 Aug;3(8):1169–1176
66. Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat. 2018 Jan;25(1):4–9
67. Giacomini E, Rizzo F, Etna MP, et al. Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients. Mult Scler. 2017 Feb;1:1352458517695892
68. Romani L, Oikonomou V, Moretti S, et al. Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 2017 May;23(5):590–600
69. McClure JE, Lameris N, Wara DW, et al. Immunochemical studies on thymosin: radioimmunoassay of thymosin et. J Lmmun. 1982;128(368):375
70. Hirokawa D, Saitoh K, 1980 Heterogeneity of thymic epithelial cells revealed by the localization of thymosin α 1 and various hydrolytic enzyme in human thymus. 4th international congress immunology, p.3.3.14 (Abstract)
71. Naylor PH, Friedman-Kien A, Hersh E, et al. Thymosin α 1 and thymosin β 4 in serum: comparison of normal, cord, homosexual and AIDS serum. Int J Immunopharmac. 1986;8:667–676
72. Chen SJ, Ko HS. Serum thymosin-alpha 1: lack of association between elevated levels and HIV infection. Clin Exp Immunol. 1987 Nov;70(2):263–267
73. Wada S, Naylor PH, Naylor CW, et al. Improved ELISA to measure thymosin alpha 1: comparison of whole and absorbed antisera. Int J Immunopharmacol. 1988;10(7):795–801
74. Naylor PH, Naylor CW, Sasaki D, et al. Utilization of HPLC-ELISA to assess serum levels of thymosin α 1 following subcutaneous administration to human subjects. J Liquid Chromatogr. 1994;17:3541–3551
75. Tuthill CW, Rudolph A, Li Y, et al. Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS. AAPS PharmSciTech. 2000 May 14;1(2):E11
76. Schulof R, Lloyd JJ, Cox J, et al. An evaluation of two different schedules of synthetic thymosin alpha 1 administration in patients with lung cancer. Preliminary results. In: Goldstein AL, Ed. Thymic hormones and lymphokines. New York: Plenum Press; 1984. p. 601–613
77. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990 Nov;19(5):390–399
78. Badamchian M, Mora CA, Baumann CA, et al. Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice. Int J Immunopharmacol. 1997 Feb;19(2):59–66
79. Liaw Y-F. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol. 1997;12(suppl):S346–S353
80. Rost KL, Wierich W, Masayuki F, et al. Pharmacokinetics of thymosin α1 after subcutaneous injection of three different formulations in healthy volunteers. Int J Clin Pharmacol Ther. 1999;37(1):51–57
81. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001 May 15; 58(10):879–85;quiz 886–8. Review
82. Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016 Oct;186(1):39–45
83. Serafino A, Pierimarchi P, Pica F, et al. Thymosin a1 as a stimulatory agent of innate cell-mediated immune response. Ann NY Acad Sci. 2012;1270:13–20
84. Torcia MG, Nencioni L, Clemente AM, et al. Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL 10 production in males. PlosONE. 2012;7:e39853
85. Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10:594–604
86. Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, et al. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012;38:J109–19
87. Veale DJ, Fearon U. What makes psoriatic and rheumatoid arthritis so different? RMD Open. 2015;1:e000025
88. Conigliaro P, Triggianese P, Perricone C, et al. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during Etanercept treatment. Clin Exp Immunol. 2014;177:234–243
89. Jou YC, Tsai YS, Hsieh HY, et al. Plasma thymosin-a1 level as a potential biomarker in urothelial and renal cell carcinoma. Urol Oncol. 2013;31:1806–1811
90. Sasaki H, Fujii Y, Masaoka A, et al. Elevated plasma thymosin-alpha1 levels in lung cancer patients. Eur J Cardiothorac Surg. 1997 Dec;12(6):885–891
91. Mitani M, Kuwabara Y, Kawamura H, et al. Significance of plasma thymosin alpha1 measurements in gastric cancer patients. World J Surg. 2000 Apr;24(4):455–458
92. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–13010
93. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2013;348:138–150
94. Ryan T, Coakley JD, Martin-Loeches I. Defects in innate and adaptive immunity in patients with sepsis and health care associated infection. Ann Transl Med. 2017 Nov;5(22):447
95. Payen D, Monneret G, Hotchkiss R. Immunotherapy - a potential new way forward in the treatment of sepsis. Crit Care. 2013 Feb 20;17(1):118
96. McGillis JP, Hall NR, Goldstein AL. Circadian rhythm of thymosin-alpha 1 in normal and thymectomized mice. J Immunol. 1983 Jul;131(1):148–151
97. Molinero P, Soutto M, Benot S, et al. Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin alpha1 and thymulin concentrations: observations in rats and humans. J Neuroimmunol. 2000;103:180–188